Table 4.

Number of countries where introducing MR-MAPs is cost-effective

Projection assumption	Higher coverage				Lower coverage
Introduction strategy	Sequential		Accelerated		Sequential		Accelerated
MR-MAP price	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
Low income	3/20	0/20	3/20	0/20	17/20	9/20	18/20	10/20
Lower middle income	10/35	6/35	9/35	5/35	25/35	20/35	28/35	22/35
Upper middle income	5/15	5/15	7/15	6/15	11/15	11/15	11/15	11/15
Total	18/70	11/70	19/70	11/70	53/70	40/70	57/70	43/70

Introducing MR-MAPs is considered to be cost-effective if the country-specific ICER is below the country-specific threshold, under a 3% annual discount rate on both incremental costs and health benefits.

ICER, incremental cost-effectiveness ratio; MR-MAP, measles-rubella microarray patch.